DCA Drug Development Company, CardioMetabolics Inc., Encouraged by Intense Public Interest in Dichloroacetate for Treatment Of Cancer

EDMONTON, Jan. 23 /CNW/ - Kimmo Lucas, President and CEO of CardioMetabolics Inc. (CMI) commented today on the increased public interest in DCA (Dichloroacetate), from unrelated news announcements referring to DCA as a "breakthrough drug for the treatment of cancer" - specifically for
patients requiring cancer chemotherapy.

"CMI's technology related to the metabolic modulator DCA shows promise in treating various conditions and disease states, including prevention of reperfusion injury in open heart surgical procedures, acute coronary syndromes, diabetes and angina. Other potential applications include obesity and cancer. The common element in treating these diverse diseases is the drug's special ability to positively impact the metabolism of energy. As well, CMI's technology extends to related DCA compounds and which appear to have similar mechanisms of action. The company has research planned or ongoing in all aforementioned areas and which is covered by intellectual property protection," said Lucas.

To date, CMI has been granted four Patents from the USPTO (United States Patent & Trademark Office) and has several other patent applications pending. Two of the issued patents relate to DCA, while the other two cover related compounds of DCA. CMI's patent coverage includes the treatment of cardiovascular diseases and metabolic conditions where ischemic or hypoxic conditions present (such as cardiac surgery), as well as the other disease states mentioned above.

CMI X-11S (DCA intravenous formulation) is the company's lead clinical stage drug product. CMI has secured permission from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) and from the CDN Therapeutic Product Directorate (TPD) to initiate Phase III clinical trials for cardiac surgery in higher risk geriatric patients. Other potential applications are earlier stage candidates and the company cautions that much work remains to develop them. Although early results are promising, it may take years of research to prove efficacy in humans.
    
CMI is currently undergoing a round of financing and in discussions with strategic drug partners. The company is focused on unlocking the potential of this exciting drug and its related compounds.

This press release may contain forward-looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents, the Company's ability to protect its intellectual property, and involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Other risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Companyto defend its patents from infringement by third parties, and the risk that  the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors are cautioned against placing undue reliance on forward-looking statements.

Background Information

DCA has the potential to help improve the lives of millions of patients. In the US alone, the combined direct and indirect cost of treatment for cardiovascular disease was estimated at $365 billion US and with diabetes at $172 billion US (American Heart Association, 2005). Global drug treatment costs for cancer worldwide are estimated at $40 billion (Market Research 2005).

CardioMetabolics Inc. (CMI) is an Edmonton-based, privately held, company. CMI was established in 2000. The Company holds the worldwide exclusive rights to the technologies which are licensed from the University of Alberta. CMI's product development focuses on the development of cost effective drugs that address unmet needs not adequately served by products currently on the market. The company's mission is to develop cost effective drugs to improve the lives of patients suffering from cardiovascular or other diseases.

 

-30-

/For further information: Kimmo Lucas, President & CEO, CardioMetabolics
Inc., Cell: (780) 722-8367/


 

Posted: January 2007

View comments

Hide
(web2)